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Abstract
Objectives: Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis have not been fully investigated.
Methods: We reviewed all cases of ATV-containing urolithiasis identified by infrared spectrophotometry among HIV-
infected patients over a 5-year period to describe their clinical features and outcome. A case-control study was performed to
identify risk factors associated with ATV-associated urolithiasis using univariate and multivariate logistic regression analyses.
Results: 30 cases of ATV-associated urolithiasis were analyzed. Patients were mostly men (87%), median age: 45.5 years,
median CD4 cell count: 443 cells/mL and 97% had plasma HIV RNA level ,50 cp/mL. Median time between the initiation of
ATV-containing regimen and the diagnosis of urolithiasis was 3.1 years. Patients presented with flank pain in 90% and
macroscopic hematuria in 82.6%, 34% had renal dysfunction and 44.8% needed ureteroscopic treatment. In univariate
analysis, chronic hepatitis C, a history of urolithiasis, prior use of indinavir, ATV duration, undetectable plasma HIV RNA, use
of ritonavir as a booster and serum free bilirubin level were associated with ATV-urolithiasis. Multivariate models retained
serum free bilirubin level (OR: 2.31, p,0.02) and either ATV duration (OR: = 1.42, p =,0.03) or a history of urolithiasis
(OR= 4.79, p,0.02) when adjusting on serum free bilirubin level as risk factors associated with urolithiasis.
Conclusions: ATV-containing urolithiasis are associated with frank clinical symptoms and may require surgical intervention.
A high serum bilirubin level, a long exposure to ATV and a history of urolithiasis are risk factors for this rare adverse event.
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Introduction
Atazanavir (ATV) is a widely used HIV protease inhibitor (PI)
both in treatment-experienced and treatment-naive patients due to
its potent antiviral activity and good safety profile [1]. Hyperbil-
irubinemia frequently occurs among patients receiving ATV due
to the inhibition of the UGT1A1 metabolic pathway, but its
clinical consequences are usually limited to mild scleral icterus.
Other rare adverse events such as urolithiasis have been reported
with ATV in postmarketing studies [2]. Indeed there have been a
few case reports of urolithiasis in patients receiving ATV-based
antiretroviral therapy (ART) [3–8]. Cohort studies have reported a
high incidence rate of urolithiasis ranging from 7 to 24 cases per
1000 person-years among patients receiving ATV-based ART [9–
10]. ATV/ritonavir (ATV/r) use was identified as an independent
risk for renal stones (HR: 21.5, 95% confidence interval (CI): 2.9–
160, p = 0.003) and may therefore represent a limitation for its use
[10]. It is therefore critical to identify risk factors for ATV-
associated urolithiasis in order to prevent or reduce the occurrence
of this adverse event. Previous reports suggested several risk factors
for ATV-induced renal stones, such as chronic renal impairment,
co-infection with hepatitis virus, and past history of renal stones
[7,9]. However, the methods used in those studies were not
adequate to determine risks factors for ATV/r-induced renal
stones. Our aim was to better describe clinical features and
outcome of patients with ATV-induced urolithiasis and to assess
risk factors for this outcome using a case-control study.
Methods
Patients with ATV-containing urolithiasis were identified from
the computerized databases of three biochemistry laboratories,
located in Paris from January 2008 to December 2012. In France
HIV infected patients followed in hospitals are all registered in the
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French Hospital Database on HIV - FHDH and give written
informed consent for their clinical records to be used in any
epidemiological study.
In this study, patient records/information was anonymized and
de-identified prior to analysis.
In all patients, the presence of ATV in the calculi was confirmed
by infrared spectrometry [11]. Patients’ charts were then reviewed
after we obtained approval by the medical staff to participate in
this study. For each case, three controls were sampled among
patients who had no history of ATV-associated urolithiasis while
treated with ATV-based regimens for at least 6 months (since this
adverse event has been reported to occur late after treatment
initiation). These controls were randomly selected from our
computerized database of patients with HIV-infection at the
Saint-Louis hospital in Paris. They were matched to their
respective cases by choosing the closest medical consultation and
biological sampling they had on the date of occurrence of ATV-
associated urolithiasis in cases. The following data were obtained
from medical charts: age, sexe, body mass index, conditions that
predispose to urolithiasis (diabetes, obesity, drugs contributing to
stone development such as sulfamide-containing coumpounds,
serum calcium level), previous ART, current ART, duration of
ATV exposure, CD4 T-cell count, plasma HIV-RNA level, CDC
AIDS classification, prior history of urolithiasis before ATV
initiation, clinical signs and symptoms of ATV-associated urolith-
iasis, imaging at diagnosis, composition of the stones, treatment
and outcome. The following parameters were also collected in
cases 6–12 months before the onset of urolithiasis, and 6–12
months later: serum creatinine, bilirubin, calcium, urine analysis.
Distributions in cases and controls were compared with the use
of Mann-Whitney test for quantitative variables and Fisher’s exact
test for qualitative variables. Statistical tests were two-sided, and P
values of less than 0.05 were considered to indicate statistical
significance. Tests for paired samples were not used, as no other
factor than the date of occurrence of ATV-associated urolithiasis
was used to match cases and controls.
A risk factor analysis was conducted to identify factors
associated with the occurrence of ATV-containing urolithiasis.
We used logistic regression modeling in an univariate analysis
among all covariates. Baseline characteristics available at ICU
admission and associated with p values lower than 0.1 by
univariate analysis or deemed clinically relevant were included
in a multivariate logistic regression selection process. Given the
number of cases, a maximum of three covariates was allowed in
the tested models. Multiple imputation by chained equation was
used to handle missing values. A stepwise Bayesian information
criterion (BIC)-based selection was repeated in 30 imputed
datasets to identify factors independently associated with urolith-
iasis. Models’ calibrations were tested by the le Cessie–van
Houwelingen goodness-of-fit test. Statistical analyses were per-
formed with R version 3.0.2 (R Development Core Team 2013; R
Foundation for Statistical Computing, Vienna, Austria).
Results
Sixty-two ATV-containing urolithiasis cases were retrieved from
the 3 biochemistry laboratories during the study period but only
30 cases could be analyzed. Patients not enrolled in our study were
those who did not live in the Paris area rendering data collection
uneasy. Characteristics of cases are depicted in Table 1. Most
patients were male, with a median age of 45.5 years. Median
duration of HIV infection was nearly 10 years. At diagnosis,
median CD4 cell count was high and similar in both groups.
Twenty-nine cases (96.7%) had plasma HIV RNA levels ,50 cp/
mL, versus 59/90 (65.6%) controls (p,0.001). Median time
between the initiation of ATV-containing regimen and the
diagnosis of urolithiasis was significantly longer in cases than in
controls (3.1 years [range: 2.2–3.8] versus 1.9 [1.2, 3.2]
respectively, p,0.009). In all but one case (96.7%) ATV daily
dose was 300 mg boosted with ritonavir 100 mg whereas only 53
patients (58.9%) in the control group received ATV/r (p,0.001).
The proportion of patients who received tenofovir, lamivudine or
emtricitabine and abacavir was similar in both groups. There was
no difference between cases and controls in terms of patients co-
morbidities, use of drugs with lithogenic potential (data not shown)
or serum calcium level. However, an history of prior use of
indinavir, prior indinavir urolithiasis and also prior urolithiasis
(any type) before ATV therapy were significantly more frequent in
cases compared to controls (44.8% versus 20%, p,0.002; 26.7%
versus 1.2%, p,0.001 and 36.7 versus 7.8%, p,0.01, respective-
ly). Finally, median serum free bilirubin was significantly higher in
cases compared to controls (49.1 mmol/l [IQR: 32.5, 56] and 30.9
[17.7, 45] respectively, ,0.004).
Clinical presentation, treatment and outcome of patients with
ATV-associated urolithiasis are described in Table 2. Infrared
spectrometry showed that kidney stones contained a high
proportion of ATV (median percentage of ATV: 89%, IQR:
59.0, 95.0). Most cases of ATV-urolithiasis were symptomatic with
renal colic or lumbar/flank pain in 90% and gross hematuria in
82.6% of cases. Complications were also frequent, with bilateral
involvement in 4 cases (14.3%), ureteral dilatation in 13 (54.2%)
and renal failure (MDRD creatinine clearance ,60 mL/min) in 9
(34.6%) patients. Intervention for stone removal was required in
13 patients (44.8%) and a double J ureteral stent was inserted in 8/
28 cases (29%). ATV-associated urolithiasis led to ATV discon-
tinuation in most patients (82.8%). Median creatinine clearance
was significantly lower at diagnosis versus 6–12 months earlier (p,
0.05) but returned to baseline, 6–12 months after urolithiasis onset
(p = 0.26). However, in the 6 patients with renal failure at the time
of ATV-urolithiasis, renal function did not normalize 6–12 months
later. Urinary pH was measured in only 6 patients at the onset of
urolithiasis and ranged from 5 to 6.9. Recurrence of urolithiasis
during follow-up was reported in 3 patients, 2 of whom were still
on ATV.
In univariate analysis, risk factors for ATV-urolithiasis were
chronic hepatitis C, a history of urolithiasis, the prior use of
indinavir, ATV duration, undetectable HIV plasma RNA, the use
of ritonavir as a booster and the serum free bilirubin level
(Table 3). Multivariate models retained serum free bilirubin level
and either ATV duration or a history of urolithiasis as factors
associated with ATV-associated urolithiasis (Table 4).
Discussion
We report here a large series of 30 cases of ATV-containing
urolithiasis that allowed us to better described the clinical features
and outcomes of this rare adverse event in HIV-infected patients
receiving an ATV-based antiretroviral regimen.
Due to our strict definition of cases based on the identification of
ATV in the calculi using infrared spectrometry we could ascertain
that the stones obtained in our patients were indeed related to
ATV use.
Patients with ATV-containing urolithiasis in our study were
mostly men, with a median age of 45.5 years, a body mass index of
22.8 kg/m2, and a low prevalence of diabetes (3.3%). They were
receiving an ATV-based regimen for a median of 3.1 years, a long
duration of exposure which is consistent with previous reports [7–
9]. The large majority of patients in our study were symptomatic
Atazanavir-Associated Urolithiasis Risk-Factors
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with flank pain and macroscopic hematuria. However, the
retrospective design of the study and our case-definition may
have probably overlooked minor clinical forms since severe cases
were more likely to be reported. Despite this limitation, it is
striking to see that 34.6% of patients presented with renal failure
(estimated creatinine clearance ,60 ml/mn) and that more than
half needed urologic intervention (lithotripsy or double J stent).
Most patients discontinued ATV following the occurrence of this
adverse event, and in those who continued treatment, the rate of
relapse was high although the number of cases remains limited in
our study. It seems reasonable though to discontinue ATV
following an episode of ATV-containing lithiasis, due to the
potential severity of the episode, the risk of relapse and the number
of alternatives available. It seems indeed that this risk of
urolithiasisurolithiasis is a distinct feature of some (atazanavir,
indinavir) but not all PIs (lopinavir, darunavir) [9–10].
In a previous report, we showed that whereas lopinavir is not
excreted in urine, pretty high concentration of ATV and
darunavir can be achieved in urine, with the detection of ATV
and darunavir crystals in a minority of patients [11]. However, the
incidence of darunavir-associated urolithiasis is much lower than
with ATV, and to our knowledge no darunavir-containing lithiasis
has yet be reported [9–10]. The reasons for these differences
between ATV and darunavir are yet unknown but could be
related to differences in solubility of the PI-crystals, the role of
urine pH (strong acidity is required to achieve optimal dissolution
of ATV), and other factors.
Since ATV is a widely used PI, it is important to identify risk
factors for urolithiasis. Our case-control study was able to identify
the level of serum free bilirubin as an independent factor
associated with a 2.31-fold increased risk of urolithiasis per 2-
fold increase in serum level (Table 4). This finding is not
unexpected as serum free bilirubin level is correlated to ATV
plasma level, since ATV inhibits the UGT1A1 pathway [13].
Hyperbilirubinemia is indeed a frequent adverse event in patients
receiving an ATV-based regimen, although the clinical conse-
quences of hyperbilirubinemia except for jaundice are limited [1].
In a recent study, hyperbilirubinemia in patients receiving an
Table 1. Baseline characteristics of HIV-infected patients with atazanavir-associated urolithiasis and controls.
Controls (n=90) Cases (n=30) p
Male [n (%)] 68 (75.6%) 26 (86.7%) 0.31
Age (years) [median (IQR)] 47 [39, 52.8] 45.5 [42, 50.5] 0.85
Body Mass Index (BMI) (kg/m2) (median [IQR]) 23 [21.1, 25.7] 22.8 [21.3, 24.2] 0.60
Diabetes [n (%)] 9 (10%) 1 (3.3%) 0.45
Duration of HIV infection (years) [median (IQR)] 12.0 [4.9, 18.3] 9.7 [4.2, 17.7] 0.47
CDC disease stage 0.20
A 48 (53.9%) 20 (66.7%)
B 14 (15.7%) 1 (3.3%)
C 27 (30.3%) 9 (30%)
Nadir CD4 (cell count, cells/mL) 204 [112, 297] 209.5 [67, 313] 0.79
CD4+ cell count, cells/mL (IQR?) 492 [344, 657] 443 [401, 620] 0.77
Plasma HIV RNA .50 cp/mL [n (%)] 59 (65.6%) 1 (3.3%) ,0.001
Duration of ATV prior to urolithiasis (years) [median (IQR)] 1.9 [1.2, 3.2] 3.1 [2.2, 3.8] ,0.009
Associated ARV therapy [(n) %]
Ritonavir (100 mg od) [(n) %] 68 (75.6%) 29 (96.7%) ,0.02
Lamivudine/emtricitabine 82 (91.1%) 26 (86.7%) 0.64
Abacavir 30 (33.3%) 10 (33.3%) 1.00
Zidovudine 6 (6.7%) 3 (10%) 0.69
Didanosine 11 (12.4%) 2 (6.7%) 0.51
Tenofovir 47 (52.8%) 16 (53.3%) 1.00
Baseline creatinine clearance* (median [IQR]) 91.9 [77.5, 99.9] 81.5 [73.1, 98.2] 0.16
Chronic liver disease
Hepatitis B 3 (3.3%) 1 (0.03%)
Hepatitis C 2 (2.2%) 4 (13.3%)
Any disease (including hepatitis) 8 (8.9%) 6 (20.0%)
Chronic kidney disease** before urolithiasis [n (%)] 7 (7.9%) 4 (14.3%) 0.29
Prior treatment with indinavir (years) [(n) %] 18 (20%) 13 (44.8%) ,0.02
Duration of indinavir (months) (median [IQR]) 0 [0, 0] 0 [0, 32] ,0.004
Previous history of indinavir-urolithiasis [n (%)] 1 (1.2%) 8 (26.7%) ,0.001
Previous history of urolithiasis before ATV therapy [n (%)] 7 (7.8%) 11 (36.7%) ,0.01
Serum calcium (mmol/L) (median [IQR]) 2.3 [2.2, 2.4] 2.3 [2.3, 2.4] 0.96
Serum free bilirubin level (mmol/L) (median [IQR]) 30.9 [17.7, 45] 49.1 [32.5, 56] ,0.004
doi:10.1371/journal.pone.0112836.t001
Atazanavir-Associated Urolithiasis Risk-Factors
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ATV-based regimen was significantly associated with UGT1A1
rs887829 T allele, higher baseline bilirubin levels and slower
plasma ATV clearance [14]. Also, ritonavir boost by inhibiting
ATV clearance increases ATV exposure and bilirubin levels,
explaining why ritonavir was found as a risk factor in the
univariate analysis, and why 29 out of 30 cases were receiving a
ritonavir-boosted ATV-based regimen. It is possible that un-
boosted ATV could be associated with a lower incidence of
Table 2. Clinical presentation and outcome of 30 patients with ATV-associated urolithiasis.
Variable n=30
Signs and symptoms [n (%)]
Renal colic/Lumbar and/or flank pain [n (%)] 27 (90)
Macroscopic hematuria [n (%)] 19 (82.6)
Cre´atinine clearance* [median (IQR)] 78.0 [45.6, 98.0]
Creatinine clearance* ,60 mL/min [n (%)] 9 (34.6)
Stone size (mm) [median (IQR)] 5.5 [3.9, 9.3]
Stone composition percentage [median (IQR)]
ATV 89.0 [59.0, 95.0]
Proteins 7.5 [3.0, 10.0]
Calcium oxalate 0 [0; 8]
Calcium phosphate 0 [0, 0]
Stone location [n (%)]
Pyelic 6 (33.3)
Ureteral 11 (61.1)
Bladder 1 (5.6)
Ureteral dilatation [n (%)] 13 (54.2)
Bilateral urolithiasis [n (%)] 4 (14.3)
Treatment [n (%)]
Medical 9 (31)
Lithotripsy 2 (6.9)
Urologic surgery 13 (44.8)
ATV discontinuation [n (%)] 24 (82.8)
Recurrence of urolithiasis [n (%)] 3 (10.7)
Cre´atinine clearance* 6–12 months after ATV-urolithiasis (mL/min) [median (IQR)] 84.5 [69.4, 96.8]
doi:10.1371/journal.pone.0112836.t002
Table 3. Risk factors for atazanavir-associated urolithiasis, univariate analysis.
OR 95% CI p
Male sex 2.1 0.66–6.69 0.21
BMI (kg/m2) 0.93 0.84–1.04 0.24
Age (years) 1 0.95–1.04 0.83
Plasma HIV RNA ,50 cp/mL 0.07 0–0.44 ,0.01
RNA ,50 cp/mL
Previous history of urolithiasis 6.86 2.35–20.03 ,0.001
Prior treatment with indinavir 3.25 1.33–7.96 ,0.01
Duration of atazanavir (per year) 1.37 1.04–1.79 ,0.03
Ritonavir (100 mg od) 9.38 1.21–72.9 ,0.04
Associated antiretroviral therapy 0.8 0.34–1.85 0.60
Creatinine clearance (baseline) 0.99 0.97–1.01 0.39
Serum free bilirubin level (per 2-fold increase) 2.08 1.19–3.62 ,0.01
Any chronic liver disease 2.56 0.81–8.11 0.11
Chronic hepatitis B 1.00 0.10–9.99 1
Chronic hepatitis C 6.77 1.17–39.07 ,0.04
doi:10.1371/journal.pone.0112836.t003
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urolithiasis although more studies would be needed to confirm this
hypothesis [15]. We were unfortunately unable to provide ATV
plasma levels in our study to support this assumption.
In our study, a history of urolithiasis was also associated with an
increased risk of ATV-containing urolithiasis. This finding can be
explained by predisposing factors for the development of
urolithiasis. Indeed, a number of patients already experienced
indinavir-associated urolithiasis in our study, another PI that is
prone to induce renal calculi and is also an inhibitor of the
UGT1A1 pathway [16]. It seems therefore cautious to avoid the
use of ATV among patients who have already experienced
urolithiasis, and in particular among those who developed
nephrolithiaisis while receiving indinavir.
Finally, the duration of ATV use was also associated with an
increased risk of ATV-associated urolithiasis in our study. This
finding could be explained by the time needed to form ATV-
crystals and stones, and is consistent with previous reports
underlining that ATV-associated urolithiasis were only reported
after a couple of years of ATV-based therapy. This finding is
however a matter of concern since it would imply that patients
under ATV-based regimen with high serum free bilirubin levels
carry a potential risk of developing urolithiasis over time.
In summary, our study has shown that ATV-containing
urolithiasis can be associated with severe clinical symptoms and
are associated with high and prolonged ATV. In those patients,
most of them receiving a ritonavir-boosted ATV-based regimen,
especially if they have a history of urolithiasis, a switch to another
antiretroviral regimen should be considered to avoid the risk of
urolithiasis.
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ALTERNATIVE MODELS WITH 2 VARIABLES
Serum free bilirubin level (per 2-fold increase) 1.94 1.12–3.36 ,0.02
Previous history of urolithiasis 4.79 1.44–15.98 ,0.02
Duration of ATV (per year) 1.42 1.04–1.93 ,0.03
Serum free bilirubin level (per 2-fold increase) 2.66 1.35–5.21 ,0.01
doi:10.1371/journal.pone.0112836.t004
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